In addition, in a melanoma antigen re-stimulation assay using MART-1 peptide-pulsed DCs, we found that post-REP CD8+ MART-1 tetramer+ TIL that received previous 4-1BB co-stimulation exhibited a superior proliferative response. The gene discussed is CD8A; the disease is melanoma.